Viatris
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company that develops, manufactures and markets generic, complex generic, branded and innovative medicines across more than 10 major therapeutic areas. Its products include treatments for cardiovascular and infectious diseases, as well as established brands such as… From the company’s description.
In fiscal 2025, Viatris reported revenue of $14.30B, down 3.0% from fiscal 2024, and a net loss of $3.51B. Its operating margin was −18.6%, and operations generated $2.32B in cash. Over the twelve months to Jun 30, 2026, revenue was $14.74B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Viatris does
In the company’s own words
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company that develops, manufactures and markets generic, complex generic, branded and innovative medicines across more than 10 major therapeutic areas. Its products include treatments for cardiovascular and infectious diseases, as well as established brands such as Lyrica, Lipitor, Celebrex and Viagra; it also provides patient-support services including diagnostic clinics, educational seminars and digital tools. Customers include pharmacies, wholesalers, distributors, payers, insurers, governments and institutions such as hospitals. Viatris reports four geographic segments: Developed Markets, Emerging Markets, JANZ, and Greater China. Formed in 2020 through the combination of Mylan and Pfizer’s Upjohn Business, the company later contributed its biosimilars portfolio to Biocon Biologics and divested its women’s healthcare, Indian API and OTC businesses. In fiscal 2025, Viatris recorded $14.30 billion in revenue and operated in more than 165 countries and territories, with over 30,000 employees. Its website is www.viatris.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CANONSBURG, PA
- Fiscal year end
- December
- CIK
- 1792044
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Viatris — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Viatris · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Viatris’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Viatris’s bonds, as funds hold them
Funds report holding 10 issues of Viatris’s debt, $1.14B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 3.52%, maturing 2026 to 2050.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Viatris and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Viatris's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Viatris's last four quarterly filings that the numbers alone won't show?”